Key Takeaways DHR is set to report Q3 2025 results on Oct. 21, with revenues estimated at $6.00 billion.Life Sciences may face softness, while Biotechnology gains from strong bioprocessing demand.Diagnostics likely grew modestly, aided by the Beckman Coulter unit and steady clinical demand.Danaher Corporation (DHR) is scheduled to release third-quarter 2025 results on Oct. 21, before market open.The Zacks Consensus Estimate for revenues is pegged at $6.00 billion, which indicates an increase of 3.4% from th ...

Core Insights - Danaher Corporation (DHR) is set to release its second-quarter 2025 results on July 22, before market open [1] Revenue Estimates - The Zacks Consensus Estimate for revenues is $5.84 billion, reflecting a 1.6% increase from the same quarter last year [2] - The consensus estimate for earnings is $1.64 per share, indicating a 4.7% decrease from the year-ago quarter [2] Segment Performance - The Life Sciences segment is expected to see a revenue decline of 3.4% to $1.71 billion due to weak demand in protein consumables, flow cytometry, and lab automation solutions [3] - The Biotechnology segment is projected to grow by 7% to $1.83 billion, driven by increased demand for bioprocessing consumables from large pharmaceutical customers [5] - The Diagnostics segment is anticipated to increase by 1.1% to $2.29 billion, supported by solid momentum in pathology and acute care diagnostics [6] Cost and Expenses - SG&A expenses are expected to rise by 5.8% to $1.55 billion, which may negatively impact the bottom line [4] - Foreign currency headwinds are likely to affect profitability due to significant international operations [4] Recent Developments - Danaher acquired Abcam plc in December 2023, enhancing its Life Sciences segment with a strong product portfolio and innovation capabilities [7] Earnings Prediction - The Earnings ESP for DHR is 0.00%, indicating no clear prediction for an earnings beat this quarter [9] - The company currently holds a Zacks Rank of 4 (Sell) [11]

Core Business Performance - Danaher Corporation has seen strong performance in its bioprocessing business, with orders increasing for the seventh consecutive quarter, and anticipates core revenues to rise in high-single-digits year-over-year for 2025 [1] - The Biotechnology segment is also performing well, with core revenues increasing by 7% year-over-year in the first quarter, and similar growth is expected for 2025 [2] Acquisitions and Growth Strategy - The company acquired Abcam plc for approximately $5.7 billion in December 2023, enhancing its Life Sciences segment and contributing to a 0.5% increase in total revenues in the first quarter [3] Shareholder Returns - Danaher is committed to returning value to shareholders, having paid dividends of $194 million in the first quarter of 2025, compared to $768 million in the same quarter of 2024, and increased its dividend by 18.5% to 32 cents per share in February 2025 [4] Segment Challenges - The Life Sciences segment faced a 4% decline in core revenues year-over-year due to lower demand in academic and government markets, as well as a sales decline in the filtration business [5] - The Diagnostics segment also struggled, with core revenues declining by 1.5% year-over-year due to sluggish demand for respiratory disease tests [8] Financial Position - Danaher reported long-term debt of $16 billion, a 3% increase sequentially, with current liabilities at $6.6 billion, exceeding cash equivalents of $2 billion, and high interest expenses of $72 million in the first quarter [9][10]